Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

It's a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies

J. Trommer, M. Ullrich, F. Reissig, SA. Brühlmann, AK. Nitt-Weber, Z. Novy, K. Hajduova, D. Kurfurstova, R. Hendrychova, J. Bouchal, M. Petrik, C. Neuber, W. Sihver, S. Stadlbauer, J. Pietzsch, M. Kreller, K. Kopka, C. Mamat, K. Zarschler

. 2025 ; 10 (1) : 31. [pub] 20250619

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25014138

BACKGROUND: Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years. The alpha-emitter 225Ac plays a key role in this clinical development due to its attractive physical and chemical properties. In this context, the macropa chelator has favorable characteristics in terms of labeling conditions and complex stability, making its derivatives exceptionally appealing for 225Ac-labeling of heat-sensitive biomolecules. However, preclinical evaluation of such 225Ac-containing molecules and comprehensive assessment of their pharmacokinetics, dosimetry and radiobiology necessitate a suitable diagnostic counterpart. Due to its attractive radiation properties, 133La represents an adequate positron-emitting radionuclide to form a matched pair with 225Ac for macropa-based radiopharmaceuticals. Herein, we describe the preparation and radiopharmacological characterization of macropa-functionalized, 133La/225Ac-labeled single-domain antibodies (sdAbs) targeting the epidermal growth factor receptor (EGFR) to demonstrate the general suitability of this theranostic pair of radionuclides. RESULTS: The synthesis of a clickable, bicyclononyne-modified macropa chelator and its site-specific conjugation to azide-modified, monovalent and biparatopic sdAbs is presented. Subsequent labeling at room temperature (rt) for 15 min resulted in molar activities of 30 MBq/nmol for 133La and 0.5 MBq/nmol for 225Ac, respectively. In vitro studies using the 133La-labeled sdAbs revealed comparable binding characteristics, but an enhanced cellular internalization of the biparatopic variant compared to its monovalent counterparts. This increased uptake consequently resulted in higher cytotoxicity of the 225Ac-labeled biparatopic conjugate. In vivo PET imaging of the 133La-labeled conjugates indicated comparable uptake and retention of the mono- and biparatopic variants in liver and kidneys, with the former showing slightly higher tumor accumulation. Ex vivo biodistribution studies conducted with 225Ac-labeled conjugates largely confirmed the findings obtained by PET imaging, albeit with a marginally higher tumor accumulation of the biparatopic 225Ac-radioimmunoconjugate. Final histological examinations of tumor and kidney tissues showed DNA damage in the renal cortex of the 225Ac-radioimmunoconjugate-treated mice, but no differences in the number of γ-H2AX-positive cells in the corresponding tumor tissues could be detected. CONCLUSIONS: We present a comprehensive study on the theranostic application of 133La and 225Ac for antibody-based biomolecules and lay the foundation for the future application of this matched pair of radionuclides towards labeling of heat-sensitive, macropa-functionalized radiopharmaceuticals in general. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41181-025-00354-7.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014138
003      
CZ-PrNML
005      
20250905141503.0
007      
ta
008      
250701s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s41181-025-00354-7 $2 doi
035    __
$a (PubMed)40536585
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trommer, Johanna $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
245    10
$a It's a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies / $c J. Trommer, M. Ullrich, F. Reissig, SA. Brühlmann, AK. Nitt-Weber, Z. Novy, K. Hajduova, D. Kurfurstova, R. Hendrychova, J. Bouchal, M. Petrik, C. Neuber, W. Sihver, S. Stadlbauer, J. Pietzsch, M. Kreller, K. Kopka, C. Mamat, K. Zarschler
520    9_
$a BACKGROUND: Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years. The alpha-emitter 225Ac plays a key role in this clinical development due to its attractive physical and chemical properties. In this context, the macropa chelator has favorable characteristics in terms of labeling conditions and complex stability, making its derivatives exceptionally appealing for 225Ac-labeling of heat-sensitive biomolecules. However, preclinical evaluation of such 225Ac-containing molecules and comprehensive assessment of their pharmacokinetics, dosimetry and radiobiology necessitate a suitable diagnostic counterpart. Due to its attractive radiation properties, 133La represents an adequate positron-emitting radionuclide to form a matched pair with 225Ac for macropa-based radiopharmaceuticals. Herein, we describe the preparation and radiopharmacological characterization of macropa-functionalized, 133La/225Ac-labeled single-domain antibodies (sdAbs) targeting the epidermal growth factor receptor (EGFR) to demonstrate the general suitability of this theranostic pair of radionuclides. RESULTS: The synthesis of a clickable, bicyclononyne-modified macropa chelator and its site-specific conjugation to azide-modified, monovalent and biparatopic sdAbs is presented. Subsequent labeling at room temperature (rt) for 15 min resulted in molar activities of 30 MBq/nmol for 133La and 0.5 MBq/nmol for 225Ac, respectively. In vitro studies using the 133La-labeled sdAbs revealed comparable binding characteristics, but an enhanced cellular internalization of the biparatopic variant compared to its monovalent counterparts. This increased uptake consequently resulted in higher cytotoxicity of the 225Ac-labeled biparatopic conjugate. In vivo PET imaging of the 133La-labeled conjugates indicated comparable uptake and retention of the mono- and biparatopic variants in liver and kidneys, with the former showing slightly higher tumor accumulation. Ex vivo biodistribution studies conducted with 225Ac-labeled conjugates largely confirmed the findings obtained by PET imaging, albeit with a marginally higher tumor accumulation of the biparatopic 225Ac-radioimmunoconjugate. Final histological examinations of tumor and kidney tissues showed DNA damage in the renal cortex of the 225Ac-radioimmunoconjugate-treated mice, but no differences in the number of γ-H2AX-positive cells in the corresponding tumor tissues could be detected. CONCLUSIONS: We present a comprehensive study on the theranostic application of 133La and 225Ac for antibody-based biomolecules and lay the foundation for the future application of this matched pair of radionuclides towards labeling of heat-sensitive, macropa-functionalized radiopharmaceuticals in general. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41181-025-00354-7.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ullrich, Martin $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000161046676
700    1_
$a Reissig, Falco $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000252030776
700    1_
$a Brühlmann, Santiago Andres $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000278406858
700    1_
$a Nitt-Weber, Anne-Kathrin $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
700    1_
$a Novy, Zbynek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0000000277162142 $7 xx0169427
700    1_
$a Hajduova, Katarina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $1 https://orcid.org/0009000030780907
700    1_
$a Kurfurstova, Daniela $u Institute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000231753131 $7 xx0269558
700    1_
$a Hendrychova, Romana $u Institute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000272726260
700    1_
$a Bouchal, Jan $u Institute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000348421720 $7 xx0034399
700    1_
$a Petrik, Milos $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic $u Czech Advanced Technology and Research Institute, Palacký University, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000313345916
700    1_
$a Neuber, Christin $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000206465808
700    1_
$a Sihver, Wiebke $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000228769925
700    1_
$a Stadlbauer, Sven $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000322765330
700    1_
$a Pietzsch, Jens $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $u School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany $1 https://orcid.org/0000000216101493
700    1_
$a Kreller, Martin $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $1 https://orcid.org/0000000324243202
700    1_
$a Kopka, Klaus $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $u School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany $u National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany $u German Cancer Consortium (DKTK), Partner Site Dresden, Fetscherstraße 74, 01307, Dresden, Germany $1 https://orcid.org/0000000348461271
700    1_
$a Mamat, Constantin $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany $u School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, Dresden, Germany $1 https://orcid.org/0000000319063186
700    1_
$a Zarschler, Kristof $u Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. k.zarschler@hzdr.de $1 https://orcid.org/0000000275714732
773    0_
$w MED00214678 $t EJNMMI radiopharmacy and chemistry $x 2365-421X $g Roč. 10, č. 1 (2025), s. 31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40536585 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141451 $b ABA008
999    __
$a ok $b bmc $g 2387974 $s 1251258
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 10 $c 1 $d 31 $e 20250619 $i 2365-421X $m EJNMMI radiopharmacy and chemistry $n EJNMMI Radiopharm Chem $x MED00214678
LZP    __
$a Pubmed-20250701

Najít záznam

Citační ukazatele

Možnosti archivace